Encoding compliance logic, transfer restrictions, and ownership records into smart contracts becomes a product institutional counterparties will pay for, rather than a one-off Faraday reference experiment. If this holds, AIxCrypto can create recurring software-like revenue; if it fails, the company remains an expense base without a validated market.

Faraday Future Robotics becomes a real deployment environment that supplies operational data and transaction activity for AIxC Hub, creating the company’s proposed RWA/EAI flywheel. If the FFAI relationship becomes commercial, it can validate the dual-pillar strategy; if not, the EAI pillar has no named deployment anchor in the filing.

Discontinuing BesTrade and C10 reduces operating complexity and redirects spending toward infrastructure products with better scale, regulatory fit, and margin potential. If focus lowers the burn rate, the PIPE can fund product-market proof; if costs stay high, shareholders are funding overhead rather than a scalable platform.

The September 2025 PIPE gives AIxCrypto enough runway to commercialize the pivot, but only if management avoids using that capital in ways that dilute or leak value away from RWA/EAI infrastructure. Cash creates option value; repeated dilution or off-strategy spending transfers that option value away from existing holders.

Legacy therapeutics and Marizyme-related exposures must be monetized, sold, or ring-fenced so the AI/blockchain capital base is not consumed by credit losses and non-core biotech obligations. If legacy assets drain cash or create impairments, the new strategy can fail even before market demand is tested.